Blade Air Mobility (BLDE) 10-Q 9 Aug 23 2023 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2023	Aug. 02, 2023
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity File Number	001-39046
Entity Registrant Name	BLADE AIR MOBILITY, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	84-1890381
Entity Address, Address Line One	55 Hudson Yards,
Entity Address, Address Line Two	14th Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10001
City Area Code	212
Local Phone Number	967-1009
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		74,114,889
Current Fiscal Year End Date	--12-31
Entity Central Index Key	0001779128
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Amendment Flag	false
Common Stock, $0.0001 par value per share
Document Information [Line Items]
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	BLDE
Security Exchange Name	NASDAQ
Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share
Document Information [Line Items]
Title of 12(b) Security	Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share
Trading Symbol	BLDEW
Security Exchange Name	NASDAQ

Unaudited Interim Condensed Con

Unaudited Interim Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 37,348	$ 43,296
Restricted cash	2,045	1,127
Accounts receivable, net of allowance of $63 and $— at June 30, 2023 and December 31, 2022	22,525	10,877
Short-term investments	132,342	150,740
Prepaid expenses and other current assets	14,710	12,086
Total current assets	208,970	218,126
Non-current assets:
Property and equipment, net	2,909	2,037
Investment in joint venture	390	390
Intangible assets, net	43,933	46,365
Goodwill	39,797	39,445
Operating right-of-use asset	23,186	17,692
Other non-current assets	998	970
Total assets	320,183	325,025
Current liabilities:
Accounts payable and accrued expenses	14,879	16,536
Deferred revenue	10,014	6,709
Operating lease liability, current	4,380	3,362
Total current liabilities	29,273	26,607
Non-current liabilities:
Warrant liability	8,979	7,083
Operating lease liability, long-term	19,833	14,970
Deferred tax liability	1,334	1,876
Total liabilities	59,419	50,536
Commitments and Contingencies (Note 8)
Stockholders' Equity
Preferred stock, $0.0001 par value, 2,000,000 shares authorized at June 30, 2023 and December 31, 2022. No shares issued and outstanding at June 30, 2023 and December 31, 2022.	0	0
Common stock, $0.0001 par value; 400,000,000 authorized; 73,169,003 and 71,660,617 shares issued at June 30, 2023 and December 31, 2022, respectively.	7	7
Additional paid in capital	383,629	375,873
Accumulated other comprehensive income	3,230	2,287
Accumulated deficit	(126,102)	(103,678)
Total stockholders' equity	260,764	274,489
Total Liabilities and Stockholders' Equity	$ 320,183	$ 325,025

Unaudited Interim Condensed C_2

Unaudited Interim Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Allowance for credit losses	$ 63	$ 0
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	400,000,000	400,000,000
Common stock, shares issued (in shares)	73,169,003	71,660,617

Unaudited Interim Condensed C_3

Unaudited Interim Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Revenue	$ 60,989	$ 35,633	$ 106,260	$ 62,263
Operating expenses
Cost of revenue	50,620	30,522	88,727	54,229
Software development	1,440	1,062	2,563	1,897
General and administrative	18,410	12,144	34,667	26,122
Selling and marketing	2,728	1,638	5,339	3,438
Total operating expenses	73,198	45,366	131,296	85,686
Loss from operations	(12,209)	(9,733)	(25,036)	(23,423)
Other non-operating (expense) income
Interest income, net	2,077	455	4,031	719
Change in fair value of warrant liabilities	(2,462)	19,266	(1,896)	21,816
Realized loss from sales of short-term investments	(14)	(1,576)	(95)	(1,712)
Total other non-operating (expense) income	(399)	18,145	2,040	20,823
(Loss) income before income taxes	(12,608)	8,412	(22,996)	(2,600)
Income tax benefit	(376)	0	(572)	0
Net (loss) income	$ (12,232)	$ 8,412	$ (22,424)	$ (2,600)
Net (loss) income per share (Note 7):
Basic (in dollars per share)	$ (0.17)	$ 0.11	$ (0.31)	$ (0.04)
Diluted (in dollars per share)	$ (0.17)	$ 0.10	$ (0.31)	$ (0.04)
Weighted-average number of shares outstanding:
Basic (in shares)	73,169,003	71,051,523	72,584,138	70,913,597
Diluted (in shares)	73,169,003	78,497,356	72,584,138	70,913,597

Unaudited Interim Condensed C_4

Unaudited Interim Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (12,232)	$ 8,412	$ (22,424)	$ (2,600)
Other comprehensive income:
Net unrealized investment income (losses)	10	(140)	39	(1,520)
Less: Reclassification adjustment for losses included currently in net (loss) income	13	1,576	64	1,712
Foreign currency translation adjustments for the period	(5)	77	840	318
Other comprehensive income	18	1,513	943	510
Comprehensive (loss) income	$ (12,214)	$ 9,925	$ (21,481)	$ (2,090)

Unaudited Interim Condensed C_5

Unaudited Interim Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Restricted shares of common stock	Common Stock	Additional Paid-In Capital	Additional Paid-In Capital Restricted shares of common stock	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning Balance (in shares) at Dec. 31, 2021			70,667,381
Beginning Balance at Dec. 31, 2021	$ 291,371		$ 7	$ 368,680		$ (898)	$ (76,418)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)			440,143
Issuance of common stock upon exercise of stock options	79			79
Issuance of common stock upon settlement of restricted stock units (in shares)			422,341
Stock-based compensation - restricted stock		$ 3,942			$ 3,942
Shares withheld related to net share settlement (in shares)			(132,539)
Shares withheld related to net share settlement	(1,011)			(1,011)
Other comprehensive income	510					510
Net (loss) income	(2,600)						(2,600)
Ending Balance (in shares) at Jun. 30, 2022			71,397,326
Ending Balance at Jun. 30, 2022	292,291		$ 7	371,690		(388)	(79,018)
Beginning Balance (in shares) at Mar. 31, 2022			70,845,636
Beginning Balance at Mar. 31, 2022	281,470		$ 7	370,794		(1,901)	(87,430)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)			325,040
Issuance of common stock upon exercise of stock options	58			58
Issuance of common stock upon settlement of restricted stock units (in shares)			356,376
Stock-based compensation - restricted stock		1,844			1,844
Shares withheld related to net share settlement (in shares)			(129,726)
Shares withheld related to net share settlement	(1,006)			(1,006)
Other comprehensive income	1,513					1,513
Net (loss) income	8,412						8,412
Ending Balance (in shares) at Jun. 30, 2022			71,397,326
Ending Balance at Jun. 30, 2022	292,291		$ 7	371,690		(388)	(79,018)
Beginning Balance (in shares) at Dec. 31, 2022			71,660,617
Beginning Balance at Dec. 31, 2022	274,489		$ 7	375,873		2,287	(103,678)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)			300,785
Issuance of common stock upon exercise of stock options	54			54
Issuance of common stock upon settlement of restricted stock units (in shares)			834,924
Stock-based compensation - restricted stock		6,018			6,018
Shares withheld related to net share settlement (in shares)			(12,079)
Shares withheld related to net share settlement	(101)			(101)
Issuance of common stock for settlement of contingent consideration (earn-out) (in shares)			384,756
Issuance of common stock for settlement of contingent consideration compensation (earn-out)	1,785			1,785
Other comprehensive income	943					943
Net (loss) income	(22,424)						(22,424)
Ending Balance (in shares) at Jun. 30, 2023			73,169,003
Ending Balance at Jun. 30, 2023	260,764		$ 7	383,629		3,230	(126,102)
Beginning Balance (in shares) at Mar. 31, 2023			72,498,822
Beginning Balance at Mar. 31, 2023	270,201		$ 7	380,852		3,212	(113,870)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon settlement of restricted stock units (in shares)			675,049
Stock-based compensation - restricted stock		$ 2,797			$ 2,797
Shares withheld related to net share settlement (in shares)			(4,868)
Shares withheld related to net share settlement	(20)			(20)
Other comprehensive income	18					18
Net (loss) income	(12,232)						(12,232)
Ending Balance (in shares) at Jun. 30, 2023			73,169,003
Ending Balance at Jun. 30, 2023	$ 260,764		$ 7	$ 383,629		$ 3,230	$ (126,102)

Unaudited Interim Condensed C_6

Unaudited Interim Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash Flows From Operating Activities:
Net loss	$ (22,424)	$ (2,600)
Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:
Depreciation and amortization	3,462	2,300
Stock-based compensation	6,018	3,942
Change in fair value of warrant liabilities	1,896	(21,816)
Realized loss from sales of short-term investments	95	1,712
Realized foreign exchange loss/(gain)	5	(5)
Accretion of interest income on held-to-maturity securities	(3,024)	0
Deferred tax benefit	(572)	0
Loss on disposal of property and equipment	0	65
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(2,625)	(3,902)
Accounts receivable	(11,630)	(4,124)
Other non-current assets	(24)	(1,152)
Operating right-of-use assets/lease liabilities	377	106
Accounts payable and accrued expenses	87	1,275
Deferred revenue	3,307	2,524
Net cash used in operating activities	(25,052)	(21,675)
Cash Flows From Investing Activities:
Purchase of property and equipment	(1,390)	(626)
Purchase of short-term investments	(135)	(453)
Proceeds from sales of short-term investments	20,532	208,700
Purchase of held-to-maturity investments	(130,145)	0
Proceeds from maturities of held-to-maturity investments	131,187	0
Net cash provided by investing activities	20,049	207,621
Cash Flows From Financing Activities:
Proceeds from the exercise of common stock options	54	79
Taxes paid related to net share settlement of equity awards	(101)	(1,011)
Net cash used in financing activities	(47)	(932)
Effect of foreign exchange rate changes on cash balances	20	7
Net (decrease) increase in cash and cash equivalents and restricted cash	(5,030)	185,021
Cash and cash equivalents and restricted cash - beginning	44,423	3,225
Cash and cash equivalents and restricted cash - ending	39,393	188,246
Reconciliation to the unaudited interim condensed consolidated balance sheets
Cash and cash equivalents	37,348	186,556
Restricted cash	2,045	1,690
Total	39,393	188,246
Non-cash investing and financing activities
New leases under ASC 842 entered into during the period	$ 7,312	$ 5,871

Description of Business and Sum

Description of Business and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Summary of Significant Accounting Policies	Description of Business and Summary of Significant Accounting Policies Description of Business Blade Air Mobility, Inc. (“Blade” or the “Company”), headquartered in New York, New York, is a technology-powered, global air mobility platform that provides consumers with a cost effective and time efficient alternative to ground transportation for congested routes. Blade’s Passenger reporting segment arranges charter and by-the-seat flights using helicopters, jets, turboprops, and amphibious seaplanes operating in various locations throughout the United States and abroad. Blade’s Medical reporting segment arranges air medical transportation of human organs in the United States, providing end-to-end logistics for transplant centers and organ procurement organizations utilizing helicopters, jets, turboprops and ground vehicles. Blade’s platform utilizes an asset-light business model, providing transportation to its customers through a network of contracted aircraft operators. Blade does not own or operate aircraft. Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Management’s opinion is that all adjustments (consisting of normal accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2023 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2023. These financial statements should be read in conjunction with the Company’s consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. Short-Term Investments Held-to-Maturity Securities The Company's investments in held-to-maturity securities consist of investment grade U.S. Treasury obligations with maturity dates of less than 365 days. The Company has the ability and intention to hold these securities until maturity. Accordingly, these securities are recorded in the Company's unaudited interim condensed consolidated balance sheet at amortized cost and interest is recorded within interest income on the Company's unaudited interim condensed consolidated statement of operations. The held-to-maturity securities balance at June 30, 2023 and December 31, 2022 was $132,342 and $130,382, respectively. The market value of the held-to-maturity securities at June 30, 2023 and December 31, 2022 was $132,318 and $130,352, respectively. Other Short-Term Investments Other short-term investments consist of highly-liquid investments available for sale. As of June 30, 2023, other short-term investments consisted of an available-for-sale, traded, debt securities fund, which is recorded at fair value with unrealized gains and losses reported, net of tax, in “Accumulated other comprehensive income (loss)”, unless unrealized losses are determined to be unrecoverable. Realized gains and losses on the sale of securities are determined by specific identification. The Company considers all available-for-sale securities as available to support current operational liquidity needs and, therefore, classifies all securities as current assets within short-term investments on the Company’s unaudited interim condensed consolidated balance sheets. These other short-term investments are excluded from disclosure under “fair value of financial instruments” due to the net asset value practical expedient. The other short-term investments balance at June 30, 2023 and December 31, 2022 was $— and $20,358, respectively. The cost of other short-term investments at June 30, 2023 and December 31, 2022 was $— and $20,460, respectively. Accounts Receivable and Allowances for Expected Credit Losses Accounts receivable consists principally of amounts due from the Company’s MediMobility Organ Transport customers, which are large hospitals that receive terms for payment. The allowance for expected credit losses on receivables is used to present accounts receivable, net at an amount that represents the Company’s estimate of the related transaction price recognized as revenue. The allowance represents an estimate of expected credit losses over the lifetime of the receivables, even if the loss is considered remote, and reflects expected recoveries of amounts previously written-off. We have determined our allowance for expected credit losses based on a specific evaluation of individual receivables and an analysis of past default experience for remaining receivables. We have historically not experienced significant losses on our receivables. We generally do not require customers to provide collateral for purchases. During the six months ended June 30, 2023, the Company recorded an allowance for credit losses of $63 for potential uncollectible accounts. Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include, but are not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected to use such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s consolidated financial statements with another public company that is not an emerging growth company or is an emerging growth company that has opted out of using the extended transition period, difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience, current business factors, and various other assumptions that the Company believes are necessary to consider to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment evolves. Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to the financial statements. Significant estimates and assumptions by management include, but are not limited to, the carrying value of long-lived assets, the fair value of intangible assets and goodwill, contingencies, the determination of whether a contract contains a lease, the allocation of consideration between lease and nonlease components, the determination of incremental borrowing rates for leases and the provision for income taxes and related deferred tax accounts. Recently Issued Accounting Standards - Adopted On January 1, 2023, we adopted ASU 2021-08, Accounting for Contract Assets and Contract Liabilities From Contracts With Customers , or ASU 2021-08, that requires acquiring companies to apply ASC 606 to recognize and measure contract assets and contract liabilities from contracts with customers acquired in a business combination consistent with those recorded by the acquiring company. The Company does not have significant contracts with customers requiring performance beyond delivery. To the extent we acquire additional companies in our existing lines of business, the adoption of this standard will not have a material impact on our results of operations or financial position. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The ASU changes accounting for credit losses on loans receivable and debt securities from an incurred loss methodology to an expected credit loss methodology. Among other things, ASU 2016-13 requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Accordingly, ASU 2016-13 requires the use of forward-looking information to form credit loss estimates. In addition, ASU 2016-13 amends the accounting for credit losses on debt securities and purchased financial assets with credit deterioration. The Company adopted ASU 2016-13 as of January 1, 2023. The company’s financial assets that are subject to the new standard are predominantly accounts receivable and short-term investments classified as held-to-maturities (e.g., U.S. Treasury obligations). The Company’s receivables consist principally of MediMobility Organ Transport customers, which are large hospitals that receive terms of 45 days or less. U.S. Treasury obligations are rated as investment grade with maturities of less than 365 days. Given our historical experience, the short duration lifetime of these financial assets and the short time horizon over which to consider expectations of future economic conditions, the company assessed that non-collection of the cost basis of these financial assets is remote. The adoption of ASU 2016-13 did not materially impact the Company’s unaudited interim condensed consolidated financial statements. Recently Issued Accounting Pronouncements - Not Adopted In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40) . The objective of this update is to simplify the accounting for convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options , (“ASC 470-20”), that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification (and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract. This amendment also further revises the guidance in ASU 260, Earnings per Share , to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments in ASU 2020-06 are effective for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company does not expect the adoption of ASU 2020-06 to have a significant impact on its consolidated financial statements.

Revenue

Revenue	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue	Revenue Revenue Recognition Short Distance products are typically purchased using the Blade App and paid for principally via credit card transactions, wire, check, customer credit, and gift cards, with payments principally collected by the Company in advance of the performance of related services. The revenue is recognized as the service is completed. Jet products are typically purchased through our Flier Relations associates and our app and are paid for principally via checks, wires and credit card. Jet payments are typically collected at the time of booking before the performance of the related service. The revenue is recognized as the service is completed. MediMobility Organ Transport products are typically purchased through our medical logistics coordinators and are paid for principally via checks and wires. Payments are generally collected after the performance of the related service in accordance with the client's payment terms. The revenue is recognized as the service is completed. The Company initially records flight sales in its unearned revenue, deferring revenue recognition until the travel occurs. Unearned revenue from customer credit and gift card purchases is recognized as revenue when a flight is flown or upon the expiration of the gift card. Unearned revenue from the Company’s passes is recognized ratably over the term of the pass. For travel that has more than one flight segment, the Company deems each segment as a separate performance obligation and recognizes revenue for each segment as travel occurs. Fees charged in association with add-on services or changes or extensions to non-refundable seats sold are considered part of the Company's passenger performance obligation. As such, those fees are deferred at the time of collection and recognized at the time the travel is provided. Contract liability is defined as entity’s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer. As of June 30, 2023 and December 31, 2022, the Company's contract liability balance was $10,014 and $6,709, respectively. This balance consists of unearned revenue, prepaid monthly and annual flight passes, customer credits and gift card obligations. Unearned revenue represents principally the flight revenues received in advance of the actual flight. Customer credits represents unearned revenue for flight reservations that typically were cancelled for good reason by the customer. The customer has one year to use the credit as payment for a future flight with the Company. Gift cards represent prepayment of flights. The Company recognizes revenue for expired customer credits and gift cards upon expiration. The table below presents a roll forward of the contract liability balance: Six Months Ended June 30, 2023 2022 Balance, beginning of period $ 6,709 $ 5,976 Additions 34,830 36,662 Revenue recognized (31,525) (34,138) Balance, end of period $ 10,014 $ 8,500 For the six months ended June 30, 2023, the Company recognized $3,405 of revenue that was included in the contract liability balance as of January 1, 2023. For the six months ended June 30, 2022, the Company recognized $3,603 of revenue that was included in the contract liability balance as of January 1, 2022. Certain governmental taxes are imposed on the Company's flight sales through a fee included in flight prices. The Company collects these fees and remits them to the appropriate government agency. These fees are excluded from revenue. The Company’s quarterly financial data is subject to seasonal fluctuations. Historically, the second and third quarter (ended on June 30 and September 30, respectively) financial results have reflected higher Short Distance travel demand and were better than the first and fourth quarter (ended March 31 and December 31) financial results. Historically, MediMobility Organ Transport demand has not been seasonal. Jet and Other revenue have historically been stronger in the first and fourth quarter (ended on March 31 and December 31, respectively) given that the Company’s by-the-seat jet service has operated only between November and April. Blade operates in three key product lines across two segments (see Note 5 - “Segment and Geographic Information” for further information on reportable segments): Passenger segment • Short Distance – Consisting primarily of helicopter and amphibious seaplane flights in the United States, Canada and Europe between 10 and 100 miles in distance. Flights are available for purchase both by-the-seat and on a full aircraft charter basis. • Jet and Other –  Consists principally of revenues from non-medical jet charter, by-the-seat jet flights between New York and South Florida, revenue from brand partners for exposure to Blade fliers and certain ground transportation services. Medical segment • MediMobility Organ Transport – Consisting of transportation of human organs for transplant and/or the medical teams supporting these services. Disaggregated revenue by product line and segment was as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Passenger Segment Short Distance $ 19,184 $ 10,963 $ 29,609 $ 15,166 Jet and Other 7,406 7,421 15,485 17,173 Total $ 26,590 $ 18,384 $ 45,094 $ 32,339 Medical Segment MediMobility Organ Transport $ 34,399 $ 17,249 $ 61,166 $ 29,924 Total $ 34,399 $ 17,249 $ 61,166 $ 29,924 Total Revenue $ 60,989 $ 35,633 $ 106,260 $ 62,263

Right-of-Use Asset and Operatin

Right-of-Use Asset and Operating Lease Liability	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Right-of-Use Asset and Operating Lease Liability	Right-of-Use Asset and Operating Lease Liability Blade’s operating leases consist of airport and heliport terminals, offices, vehicles and aircraft leases that are embedded within certain capacity purchase agreements (“CPAs”). Upon meeting certain criteria as stated in ASC 842 Leases , the lease component of a capacity purchase agreement would be accounted for as an embedded lease, with a corresponding balance included in the operating right-of-use (“ROU”) asset and lease liability. During the six months ended June 30, 2023, the Company has added the following leases in accordance with ASC 842, the details of which are discussed as follows. A CPA for three aircraft became effective in February 2023 for a three-year term ending February 14, 2026 (previous term was less than one year). In case of early termination by Blade, a one-year revenue guarantee will be pro-rated to the date of the termination. In addition, Blade has the right for immediate termination with no penalty if a government authority enacts travel restrictions. A CPA for seven aircraft was restated and amended in March 2023 for an additional two years for a total five-year term, ending March 31, 2028 (previous term was for three-years ending March 31, 2025 for six aircraft). Blade has the right to terminate the agreement without cause upon 60 days’ written notice, upon such termination a one-year flight hour guarantee will be pro-rated to the date of the termination and the operator will be entitled to retain any unapplied deposit paid by Blade at the time of such termination, in addition, Blade has the right for immediate termination with no penalty if a government authority enacts travel restrictions. The Company allocated the consideration in the capacity purchase agreements to the lease and non-lease components based on their relative standalone value. The non-lease components for these agreements primarily consist of the costs associated with flight operations. The Company determined its best estimate of the standalone value of the individual components by considering observable information from publicly available market rates. See Note 8, “Commitments and Contingencies”, for additional information about our capacity purchase agreements. Balance sheet information related to the Company’s leases is presented below: June 30, 2023 December 31, 2022 Operating leases: Operating right-of-use asset $ 23,186 $ 17,692 Operating lease liability, current 4,380 3,362 Operating lease liability, long-term 19,833 14,970 As of June 30, 2023, included in the table above is $20,691, $2,729 and $18,921 of operating right-of-use asset, current operating lease liability, and long-term operating lease liability, respectively, under aircraft leases that are embedded within the capacity purchase agreements. As of December 31, 2022, included in the table above is $14,916, $1,748 and $13,705 of operating right-of-use asset, current operating lease liability, and long-term operating lease liability, respectively, under aircraft leases that are embedded within the capacity purchase agreements. The following provides details of the Company’s lease expense: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Lease cost: Short-term lease cost $ 126 $ 59 $ 220 $ 97 Operating lease cost 494 227 961 410 Operating lease cost - Cost of revenue 1,150 250 2,140 250 Total $ 1,770 $ 536 $ 3,321 $ 757 Operating lease costs related to aircraft leases that are embedded within capacity purchase agreements are reported as part of Cost of revenue. Other information related to leases is presented below: June 30, 2023 Weighted-average discount rate – operating lease 9.10 % Weighted-average remaining lease term – operating lease (in years) 6.7 As of June 30, 2023, the expected annual minimum lease payments of the Company’s operating lease liabilities were as follows: For the Year Ended December 31 Remainder of 2023 $ 3,275 2024 6,189 2025 5,030 2026 3,997 2027 3,857 Thereafter 10,597 Total future minimum lease payments, undiscounted 32,945 Less: Imputed interest for leases in excess of one year (8,732) Present value of future minimum lease payments $ 24,213

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation Stock Option Awards Following is a summary of stock option activities for the six months ended June 30, 2023: Options Weighted Weighted Average Grant Date Fair Value Weighted Average Remaining Life (years) Intrinsic Value Outstanding – January 1, 2023 7,603,864 $ 0.19 $ 0.21 4.6 $ 25,795 Granted — — — Exercised (300,785) 0.18 0.24 Forfeited — — — Outstanding – June 30, 2023 7,303,079 $ 0.19 $ 0.21 4.1 $ 27,402 Exercisable as of June 30, 2023 7,303,079 $ 0.19 $ 0.21 4.1 $ 27,402 Restricted Stock During the three months ended June 30, 2023, the Company granted an aggregate of 97,846 of the Company's restricted stock units (“RSUs”) to various employees, officers, directors, consultants, and service providers under the Blade Air Mobility, Inc. 2021 Omnibus Incentive Plan. The RSUs have various vesting dates, ranging from vesting on the grant date to as late as four years from the date of grant. The Company's current default tax withholding method for the vesting of RSUs is the sell-to-cover method, under which shares with a market value equivalent to the estimated tax withholding obligation are withheld from the holder of the RSUs upon vesting and sold on behalf of such holder to cover their applicable tax withholding liability, and the cash proceeds from such sales are then remitted by the Company to the applicable tax authorities. This approach is used for the vesting of RSUs held by the majority of the Company’s employees, including all of the Company’s Section 16 “officers” as defined by Section 16 of the Securities and Exchange Act of 1934, as amended. Restricted Stock Units Weighted Average Grant Date Fair Value Non-vested – January 1, 2023 7,466,636 $ 5.52 Granted 275,235 3.11 Vested (834,924) 6.61 Forfeited (126,283) 5.77 Non-vested – June 30, 2023 6,780,664 $ 5.29 Stock-Based Compensation Expense Stock-based compensation expense for stock options and restricted stock units in the unaudited interim condensed consolidated statements of operations is summarized as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Software development $ 293 $ 254 $ 461 $ 529 General and administrative(1) 2,376 1,495 5,012 3,218 Selling and marketing 128 95 206 195 Total stock-based compensation expense $ 2,797 $ 1,844 $ 5,679 $ 3,942 ________ (1) For the six months ended June 30, 2023, the Company included a credit of $339 in connection with the settlement of the equity-based portion of contingent consideration related to the acquisition of Trinity Air Medical, Inc. that was paid in the first quarter of 2023 in respect of 2022 results.

Segment and Geographic Informat

Segment and Geographic Information	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Segment and Geographic Information	Segment and Geographic Information Segment Information Operating segments are defined as components of an enterprise that engage in business activities for which discrete financial information is available that is evaluated regularly by the chief operating decision maker (“CODM”) and is used in resource allocation and performance assessments. In addition, per ASC 280, Segment Reporting, paragraph 280-10-50-11, two or more operating segments may be aggregated into a single reported segment if the segments have similar economic characteristics. The Company has identified two reporting segments - Passenger and Medical. Our CODM is our senior management team. Our senior management team regularly reviews discrete information for those two reporting segments. The Passenger segment consists of our two product lines Short Distance and Jet and Other. The Medical segment consists of the MediMobility Organ Transport product line. Our product lines are defined in Note 2 in the Revenue Recognition section. The CODM evaluates the performance of the segments and allocates resources primarily based on their respective revenue , Flight Profit and Flight Margins. Flight Profit is defined as revenue less cost of revenue. Cost of revenue consists of flight costs paid to operators of aircraft and cars, landing fees, ROU asset amortization and internal costs incurred in generating ground transportation revenue using the Company’s owned cars. Flight Margin for a period is defined as Flight Profit for the period divided by revenue for the same period. The CODM does not evaluate operating segments or allocate resources using asset information and, accordingly, asset information by segment is not presented herein. The following table reflects certain financial data of the Company’s reportable segments: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Segment revenue Passenger $ 26,590 $ 18,384 $ 45,094 $ 32,339 Medical 34,399 17,249 61,166 29,924 Total revenue $ 60,989 $ 35,633 $ 106,260 $ 62,263 Segment Flight Profit Passenger $ 4,642 $ 2,478 $ 7,454 $ 3,167 Medical 5,727 2,633 10,079 4,867 Total Flight Profit $ 10,369 $ 5,111 $ 17,533 $ 8,034 Reconciling items: All other operating costs(1) (22,578) (14,844) (42,569) (31,457) Loss from operations $ (12,209) $ (9,733) $ (25,036) $ (23,423) Segment net income (loss) Passenger $ (3,837) $ (2,326) $ (8,955) $ (7,842) Medical (497) 694 1,140 1,216 Net loss from reportable segments (4,334) (1,632) (7,815) (6,626) Unallocated corporate costs & software development(2) (7,875) (8,101) (17,221) (16,797) Other non-operating income (399) 18,145 2,040 20,823 Loss before income taxes $ (12,608) $ 8,412 $ (22,996) $ (2,600) Segment Flight Margin Passenger 17.5 % 13.5 % 16.5 % 9.8 % Medical 16.6 % 15.3 % 16.5 % 16.3 % Total Flight Margin 17.0 % 14.3 % 16.5 % 12.9 % June 30, December 31, Goodwill Passenger $ 26,469 $ 26,117 Medical 13,328 13,328 Total goodwill $ 39,797 $ 39,445 ________ (1) All other operating costs consists of direct costs of service delivery, staff, selling and marketing as well as allocated staff, general and administrative expenses. (2) Unallocated corporate costs & software development includes costs that are not directly attributable to our reportable segments. Corporate costs also include shared costs such as finance, accounting, tax, human resources, information technology, legal costs and costs of the development of our application. Geographic Information Revenue by geography is based on where the flight’s operator is based. Long-lived assets, net includes property and equipment, net and operating right-of-use assets. Summary financial data attributable to various geographic regions for the periods indicated is as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Revenue United States $ 51,991 $ 33,103 $ 89,990 $ 57,946 Other 8,998 2,530 16,270 4,317 Total revenue $ 60,989 $ 35,633 $ 106,260 $ 62,263 June 30, December 31, Long-lived assets United States $ 13,320 $ 7,195 Other 12,775 12,534 Total long-lived assets $ 26,095 $ 19,729

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company’s effective tax rate represents the Company’s estimated tax rate for the year based on projected income and the mix of income among the various foreign tax jurisdictions, adjusted for discrete transactions occurring during the period. Fo r the three months ended June 30, 2023 and 2022, income tax benefit was $376 and $—, respectively. For the six months ended June 30, 2023 and 2022, income tax benefit was $572 and $—, respectively. The tax benefit in the 2023 period is attributable to Blade France. The difference in the tax benefit in the 2023 period compared to the 2022 period is attributable to the mix of pretax profits from foreign operations and the mix of tax rates in those jurisdictions, while no offsetting tax benefits arising from the Company’s U.S. and Canada net operating losses.

Net Earnings (Loss) per Common

Net Earnings (Loss) per Common Share	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Net Earnings (Loss) per Common Share	Net Earnings (Loss) per Common ShareBasic earnings (loss) per common share is computed by dividing net earnings (loss) by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per common share is computed by dividing net earnings (loss) by the weighted average number of common shares outstanding, plus the impact of common shares, if dilutive, resulting from the exercise of outstanding stock options, restricted shares, and warrants. A reconciliation of net earnings (loss) and common stock share amounts used in the computation of basic and diluted earnings (loss) per common share is presented below. Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Basic and dilutive earnings (loss) per common share: Net income (loss) attributable to Blade Air Mobility, Inc. $ (12,232) $ 8,412 $ (22,424) $ (2,600) Less: Undistributed earnings allocated to nonvested restricted stockholders — (256) — — Basic net earnings (loss) available to common stockholders (12,232) 8,156 (22,424) (2,600) Add: Undistributed earnings allocated to nonvested restricted stockholders — 256 — — Less: Reallocation of undistributed loss to nonvested restricted stockholders — (233) — — Diluted net earnings (loss) available to common stockholders (12,232) $ 8,179 $ (22,424) $ (2,600) Total weighted-average basic common shares outstanding 73,169,003 71,051,523 72,584,138 70,913,597 Effect of dilutive securities: Stock options — 7,445,833 — — Total effect of dilutive securities — 7,445,833 — — Total weighted-average diluted common shares outstanding 73,169,003 78,497,356 72,584,138 70,913,597 Net (loss) earnings per common share: Basic earnings (loss) per common share $ (0.17) $ 0.11 $ (0.31) $ (0.04) Dilutive earnings (loss) per common share $ (0.17) $ 0.10 $ (0.31) $ (0.04) The following table represents common stock equivalents that were excluded from the computation of diluted earnings (loss) per common share for the three and six months ended June 30, 2023 and 2022 because the effect of their inclusion would be anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Warrants to purchase shares of common stock 14,166,644 14,166,644 14,166,644 14,166,644 Options to purchase shares of common stock 7,303,079 — 7,303,079 7,644,533 Restricted shares of common stock 6,780,664 1,051,549 6,780,664 2,354,229 Total potentially dilutive securities 28,250,387 15,218,193 28,250,387 24,165,406

Commitment and Contingencies

Commitment and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Capacity Purchase Agreements Blade has contractual relationships with various aircraft operators to provide aircraft service. Under these Capacity Purchase Agreements (“CPAs”), the Company pays the operator contractually agreed fees (carrier costs) for operating these flights. The fees are generally based on fixed hourly rates for flight time multiplied by hours flown. Under these CPAs, the Company is also responsible for landing fees and other costs, which are either passed through by the operator to the Company without any markup or directly incurred by the Company. As of June 30, 2023, the Company has remaining unfulfilled obligations under agreements with various aircraft operators to provide aircraft service. The remaining unfulfilled obligation includes amounts within operating lease liability related to aircraft leases embedded within our capacity purchase agreements as discussed in Note 3 – Right-of-Use Asset and Operating Lease Liability. These future unfulfilled obligations were as follows: For the Year Ended December 31 Total Unfulfilled Obligation Immediate Termination (1) Termination for Convenience (2) Remainder of 2023 $ 8,892 $ 2,711 $ 2,711 2024 18,876 10,780 3,733 2025 21,119 13,024 2,524 2026 19,784 11,689 1,189 2027 18,595 10,500 — 2028 18,595 10,500 — 2029 - 2032 (each year) 8,095 — — __________ (1) Within total unfulfilled obligation, the following amounts are where Blade has the ability for immediate termination if a government authority enacts travel restrictions. (2) Within total unfulfilled obligation, the following amounts are where Blade could terminate for convenience upon 30 or 60 days’ notice, with a one-year annual minimum guarantee being pro-rated as of the termination date. Legal and Environmental From time to time, we may be a party to litigation that arises in the ordinary course of business. Other than described below, we do not have any pending litigation that, separately or in the aggregate, would, in the opinion of management, have a material adverse effect on its results of operations, financial condition or cash flows. As of June 30, 2023, management believes, after considering a number of factors, including (but not limited to) the information currently available, the views of legal counsel, the nature of contingencies to which the Company is subject and prior experience, that the ultimate disposition of these other litigation and claims will not materially affect the Company's consolidated financial position or results of operations. The Company records liabilities for legal and environmental claims when a loss is probable and reasonably estimable. These amounts are recorded based on the Company's assessments of the likelihood of their eventual disposition. In July 2022, Trinity Air Medical, LLC, a wholly owned subsidiary of Blade Urban Air Mobility, Inc., received a federal grand jury subpoena seeking records related to the provision of transplant transportation services. On August 2, 2023, the Company received notice that the grand jury investigation into the transplant transportation services industry has been closed and that the Company is no longer bound by the obligations placed on it by the subpoena. Contingent Consideration Compensation (earn-out) On September 15, 2021, the Company completed its acquisition of 100% of Trinity Air Medical, Inc. (“Trinity”) shares. In connection with the Trinity acquisition, potential earn-out payments may be made contingent upon Trinity’s achievement of an EBITDA target for the year 2023. The earn-out is calculated and is to be paid in the beginning of the calendar year 2024. The sellers are eligible for the earn-out only while employed with the Company, classifying it as compensation expense. At least 70% of the payment is required to be made in cash. For the six months ended June 30, 2023, the Company included an estimate of $3,000 in connection with Trinity’s contingent consideration compensation (earn-out) with a corresponding amount within accounts payable and accrued expenses, the expected final payment is evenly recognized throughout the year as the sellers render their services.

Warrant Liabilities

Warrant Liabilities	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Warrant Liabilities	Warrant Liabilities Warrants — Public Warrants may only be exercised for a whole number of shares. The Public Warrants became exercisable on June 7, 2021. The Public Warrants will expire on May 7, 2026 or earlier upon redemption or liquidation. Redemptions of Warrants for Cash — Once the warrants become exercisable, the Company may redeem the Public Warrants: • in whole and not in part; • at a price of $0.01 per warrant; • upon not less than 30 days’ prior written notice of redemption to each warrant holder; and • if, and only if, the reported last sale price of the Company’s common stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending three Redemption of Warrants for Shares of Common Stock — Commencing ninety days after the warrants become exercisable, the Company may redeem the outstanding warrants: • in whole and not in part; • at a price equal to a number of shares of common stock to be determined, based on the redemption date and the fair market value of the Company’s common stock; • upon a minimum of 30 days’ prior written notice of redemption; • if, and only if, the last reported sale price of the Company’s common stock equals or exceeds $10.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations, and the like) on the trading day prior to the date on which the Company sends the notice of redemption to the warrant holders; and • if, and only if, there is an effective registration statement covering the shares of common stock issuable upon exercise of the warrants and a current prospectus relating thereto is available throughout the 30-day period after the written notice of redemption is given. If the Company calls the Public Warrants for redemption for cash, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis”, as described in the warrant agreement. The exercise price and number of shares of common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, recapitalization, reorganization, merger, or consolidation. However, except as described below, the warrants will not be adjusted for issuance of common stock at a price below its exercise price. Additionally, in no event will the Company be required to net-cash settle the warrants. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the initial public offering, except that the Private Placement Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. Level 3: Unobservable inputs based on management’s assessment of the assumptions that market participants would use in pricing the asset or liability. The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2023 and December 31, 2022, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. Level June 30, 2023 December 31, 2022 Warrant liabilities - Public Warrants 1 $ 5,810 $ 4,583 Warrant liabilities - Private Warrants 2 3,169 2,500 Fair value of aggregate warrant liabilities $ 8,979 $ 7,083 The Warrants were accounted for as liabilities in accordance with ASC 815-40 and are presented within “Warrant liability” on the Company’s unaudited interim condensed consolidated balance sheets. The warrant liabilities are measured at fair value upon assumption and on a recurring basis, with changes in fair value presented within “Change in fair value of warrant liabilities” in the unaudited interim condensed consolidated statements of operations. The Public Warrants are considered part of Level 1 of the fair value hierarchy, as those securities are traded on an active public market. At May 7, 2021 and thereafter, the Company valued the Private Warrants using Level 2 of the fair value hierarchy. The Company used the value of the Public Warrants as an approximation of the value of the Private Warrants as they are substantially similar to the Public Warrants, but not directly traded or quoted on an active market. Subsequent measurement The following table presents the changes in fair value of the warrant liabilities: Public Warrants Private Placement Warrants Total Warrant Liability Fair value as of January 1, 2023 $ 4,583 $ 2,500 $ 7,083 Change in fair value of warrant liabilities 1,227 669 1,896 Fair value as of June 30, 2023 $ 5,810 $ 3,169 $ 8,979

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventsThe Company has completed an evaluation of all subsequent events through the filing of this Quarterly Report on Form 10-Q to ensure that these unaudited interim condensed consolidated financial statements include appropriate disclosure of events both recognized in the unaudited interim condensed consolidated financial statements and events which occurred but were not recognized in the unaudited interim condensed consolidated financial statements. The Company has concluded that no subsequent event has occurred that requires disclosure.

Description of Business and S_2

Description of Business and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Management’s opinion is that all adjustments (consisting of normal accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2023 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2023. These financial statements should be read in conjunction with the Company’s consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.
Short-Term Investments	Short-Term Investments Held-to-Maturity Securities
Accounts Receivable and Allowance for Expected Credit Losses	Accounts Receivable and Allowances for Expected Credit Losses Accounts receivable consists principally of amounts due from the Company’s MediMobility Organ Transport customers, which are large hospitals that receive terms for payment. The allowance for expected credit losses on receivables is used to present accounts receivable, net at an amount that represents the Company’s estimate of the related transaction price recognized as revenue. The allowance represents an estimate of expected credit losses over the lifetime of the receivables, even if the loss is considered remote, and reflects expected recoveries of amounts previously written-off. We have determined our allowance for expected credit losses based on a specific evaluation of individual receivables and an analysis
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience, current business factors, and various other assumptions that the Company believes are necessary to consider to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment evolves. Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to the financial statements. Significant estimates and assumptions by management include, but are not limited to, the carrying value of long-lived assets, the fair value of intangible assets and goodwill, contingencies, the determination of whether a contract contains a lease, the allocation of consideration between lease and nonlease components, the determination of incremental borrowing rates for leases and the provision for income taxes and related deferred tax accounts.
Recently Issued Accounting Standards - Adopted and Recently Issued Accounting Pronouncements - Not Adopted	Recently Issued Accounting Standards - Adopted On January 1, 2023, we adopted ASU 2021-08, Accounting for Contract Assets and Contract Liabilities From Contracts With Customers , or ASU 2021-08, that requires acquiring companies to apply ASC 606 to recognize and measure contract assets and contract liabilities from contracts with customers acquired in a business combination consistent with those recorded by the acquiring company. The Company does not have significant contracts with customers requiring performance beyond delivery. To the extent we acquire additional companies in our existing lines of business, the adoption of this standard will not have a material impact on our results of operations or financial position. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The ASU changes accounting for credit losses on loans receivable and debt securities from an incurred loss methodology to an expected credit loss methodology. Among other things, ASU 2016-13 requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Accordingly, ASU 2016-13 requires the use of forward-looking information to form credit loss estimates. In addition, ASU 2016-13 amends the accounting for credit losses on debt securities and purchased financial assets with credit deterioration. The Company adopted ASU 2016-13 as of January 1, 2023. The company’s financial assets that are subject to the new standard are predominantly accounts receivable and short-term investments classified as held-to-maturities (e.g., U.S. Treasury obligations). The Company’s receivables consist principally of MediMobility Organ Transport customers, which are large hospitals that receive terms of 45 days or less. U.S. Treasury obligations are rated as investment grade with maturities of less than 365 days. Given our historical experience, the short duration lifetime of these financial assets and the short time horizon over which to consider expectations of future economic conditions, the company assessed that non-collection of the cost basis of these financial assets is remote. The adoption of ASU 2016-13 did not materially impact the Company’s unaudited interim condensed consolidated financial statements. Recently Issued Accounting Pronouncements - Not Adopted In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40) . The objective of this update is to simplify the accounting for convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options , (“ASC 470-20”), that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification (and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract. This amendment also further revises the guidance in ASU 260, Earnings per Share , to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments in ASU 2020-06 are effective for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company does not expect the adoption of ASU 2020-06 to have a significant impact on its consolidated financial statements.
Revenue Recognition and Cost of Revenue	Revenue Recognition Short Distance products are typically purchased using the Blade App and paid for principally via credit card transactions, wire, check, customer credit, and gift cards, with payments principally collected by the Company in advance of the performance of related services. The revenue is recognized as the service is completed. Jet products are typically purchased through our Flier Relations associates and our app and are paid for principally via checks, wires and credit card. Jet payments are typically collected at the time of booking before the performance of the related service. The revenue is recognized as the service is completed. MediMobility Organ Transport products are typically purchased through our medical logistics coordinators and are paid for principally via checks and wires. Payments are generally collected after the performance of the related service in accordance with the client's payment terms. The revenue is recognized as the service is completed. The Company initially records flight sales in its unearned revenue, deferring revenue recognition until the travel occurs. Unearned revenue from customer credit and gift card purchases is recognized as revenue when a flight is flown or upon the expiration of the gift card. Unearned revenue from the Company’s passes is recognized ratably over the term of the pass. For travel that has more than one flight segment, the Company deems each segment as a separate performance obligation and recognizes revenue for each segment as travel occurs. Fees charged in association with add-on services or changes or extensions to non-refundable seats sold are considered part of the Company's passenger performance obligation. As such, those fees are deferred at the time of collection and recognized at the time the travel is provided. Contract liability is defined as entity’s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer. As of June 30, 2023 and December 31, 2022, the Company's contract liability balance was $10,014 and $6,709, respectively. This balance consists of unearned revenue, prepaid monthly and annual flight passes, customer credits and gift card obligations. Unearned revenue represents principally the flight revenues received in advance of the actual flight. Customer credits represents unearned revenue for flight reservations that typically were cancelled for good reason by the customer. The customer has one year to use the credit as payment for a future flight with the Company. Gift cards represent prepayment of flights. The Company recognizes revenue for expired customer credits and gift cards upon expiration. The table below presents a roll forward of the contract liability balance: Six Months Ended June 30, 2023 2022 Balance, beginning of period $ 6,709 $ 5,976 Additions 34,830 36,662 Revenue recognized (31,525) (34,138) Balance, end of period $ 10,014 $ 8,500 For the six months ended June 30, 2023, the Company recognized $3,405 of revenue that was included in the contract liability balance as of January 1, 2023. For the six months ended June 30, 2022, the Company recognized $3,603 of revenue that was included in the contract liability balance as of January 1, 2022. Certain governmental taxes are imposed on the Company's flight sales through a fee included in flight prices. The Company collects these fees and remits them to the appropriate government agency. These fees are excluded from revenue. The Company’s quarterly financial data is subject to seasonal fluctuations. Historically, the second and third quarter (ended on June 30 and September 30, respectively) financial results have reflected higher Short Distance travel demand and were better than the first and fourth quarter (ended March 31 and December 31) financial results. Historically, MediMobility Organ Transport demand has not been seasonal. Jet and Other revenue have historically been stronger in the first and fourth quarter (ended on March 31 and December 31, respectively) given that the Company’s by-the-seat jet service has operated only between November and April. Blade operates in three key product lines across two segments (see Note 5 - “Segment and Geographic Information” for further information on reportable segments): Passenger segment • Short Distance – Consisting primarily of helicopter and amphibious seaplane flights in the United States, Canada and Europe between 10 and 100 miles in distance. Flights are available for purchase both by-the-seat and on a full aircraft charter basis. • Jet and Other –  Consists principally of revenues from non-medical jet charter, by-the-seat jet flights between New York and South Florida, revenue from brand partners for exposure to Blade fliers and certain ground transportation services.
Fair Value Measurements	The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. Level 3: Unobservable inputs based on management’s assessment of the assumptions that market participants would use in pricing the asset or liability.

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Rollforward of Contract Liability Balance	The table below presents a roll forward of the contract liability balance: Six Months Ended June 30, 2023 2022 Balance, beginning of period $ 6,709 $ 5,976 Additions 34,830 36,662 Revenue recognized (31,525) (34,138) Balance, end of period $ 10,014 $ 8,500
Disaggregated Revenue by Product Line	Disaggregated revenue by product line and segment was as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Passenger Segment Short Distance $ 19,184 $ 10,963 $ 29,609 $ 15,166 Jet and Other 7,406 7,421 15,485 17,173 Total $ 26,590 $ 18,384 $ 45,094 $ 32,339 Medical Segment MediMobility Organ Transport $ 34,399 $ 17,249 $ 61,166 $ 29,924 Total $ 34,399 $ 17,249 $ 61,166 $ 29,924 Total Revenue $ 60,989 $ 35,633 $ 106,260 $ 62,263

Right-of-Use Asset and Operat_2

Right-of-Use Asset and Operating Lease Liability (Tables)	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Supplemental Balance Sheet Information Related to Leases	Balance sheet information related to the Company’s leases is presented below: June 30, 2023 December 31, 2022 Operating leases: Operating right-of-use asset $ 23,186 $ 17,692 Operating lease liability, current 4,380 3,362 Operating lease liability, long-term 19,833 14,970
Schedule of Lease Expense and Other Lease Information	The following provides details of the Company’s lease expense: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Lease cost: Short-term lease cost $ 126 $ 59 $ 220 $ 97 Operating lease cost 494 227 961 410 Operating lease cost - Cost of revenue 1,150 250 2,140 250 Total $ 1,770 $ 536 $ 3,321 $ 757 Other information related to leases is presented below: June 30, 2023 Weighted-average discount rate – operating lease 9.10 % Weighted-average remaining lease term – operating lease (in years) 6.7
Schedule of Expected Annual Minimum Lease Payments	As of June 30, 2023, the expected annual minimum lease payments of the Company’s operating lease liabilities were as follows: For the Year Ended December 31 Remainder of 2023 $ 3,275 2024 6,189 2025 5,030 2026 3,997 2027 3,857 Thereafter 10,597 Total future minimum lease payments, undiscounted 32,945 Less: Imputed interest for leases in excess of one year (8,732) Present value of future minimum lease payments $ 24,213

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Summary of Stock Option Activities	Following is a summary of stock option activities for the six months ended June 30, 2023: Options Weighted Weighted Average Grant Date Fair Value Weighted Average Remaining Life (years) Intrinsic Value Outstanding – January 1, 2023 7,603,864 $ 0.19 $ 0.21 4.6 $ 25,795 Granted — — — Exercised (300,785) 0.18 0.24 Forfeited — — — Outstanding – June 30, 2023 7,303,079 $ 0.19 $ 0.21 4.1 $ 27,402 Exercisable as of June 30, 2023 7,303,079 $ 0.19 $ 0.21 4.1 $ 27,402
Summary of Restricted Stock Activity	Restricted Stock Units Weighted Average Grant Date Fair Value Non-vested – January 1, 2023 7,466,636 $ 5.52 Granted 275,235 3.11 Vested (834,924) 6.61 Forfeited (126,283) 5.77 Non-vested – June 30, 2023 6,780,664 $ 5.29
Summary of Stock-based Compensation Expense	Stock-based compensation expense for stock options and restricted stock units in the unaudited interim condensed consolidated statements of operations is summarized as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Software development $ 293 $ 254 $ 461 $ 529 General and administrative(1) 2,376 1,495 5,012 3,218 Selling and marketing 128 95 206 195 Total stock-based compensation expense $ 2,797 $ 1,844 $ 5,679 $ 3,942 ________ (1) For the six months ended June 30, 2023, the Company included a credit of $339 in connection with the settlement of the equity-based portion of contingent consideration related to the acquisition of Trinity Air Medical, Inc. that was paid in the first quarter of 2023 in respect of 2022 results.

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Schedule of Certain Financial Data by Reportable Segment	The following table reflects certain financial data of the Company’s reportable segments: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Segment revenue Passenger $ 26,590 $ 18,384 $ 45,094 $ 32,339 Medical 34,399 17,249 61,166 29,924 Total revenue $ 60,989 $ 35,633 $ 106,260 $ 62,263 Segment Flight Profit Passenger $ 4,642 $ 2,478 $ 7,454 $ 3,167 Medical 5,727 2,633 10,079 4,867 Total Flight Profit $ 10,369 $ 5,111 $ 17,533 $ 8,034 Reconciling items: All other operating costs(1) (22,578) (14,844) (42,569) (31,457) Loss from operations $ (12,209) $ (9,733) $ (25,036) $ (23,423) Segment net income (loss) Passenger $ (3,837) $ (2,326) $ (8,955) $ (7,842) Medical (497) 694 1,140 1,216 Net loss from reportable segments (4,334) (1,632) (7,815) (6,626) Unallocated corporate costs & software development(2) (7,875) (8,101) (17,221) (16,797) Other non-operating income (399) 18,145 2,040 20,823 Loss before income taxes $ (12,608) $ 8,412 $ (22,996) $ (2,600) Segment Flight Margin Passenger 17.5 % 13.5 % 16.5 % 9.8 % Medical 16.6 % 15.3 % 16.5 % 16.3 % Total Flight Margin 17.0 % 14.3 % 16.5 % 12.9 % June 30, December 31, Goodwill Passenger $ 26,469 $ 26,117 Medical 13,328 13,328 Total goodwill $ 39,797 $ 39,445 ________ (1) All other operating costs consists of direct costs of service delivery, staff, selling and marketing as well as allocated staff, general and administrative expenses. (2) Unallocated corporate costs & software development includes costs that are not directly attributable to our reportable segments. Corporate costs also include shared costs such as finance, accounting, tax, human resources, information technology, legal costs and costs of the development of our application.
Summary of Financial Data Attributable to Various Geographic Regions	Summary financial data attributable to various geographic regions for the periods indicated is as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Revenue United States $ 51,991 $ 33,103 $ 89,990 $ 57,946 Other 8,998 2,530 16,270 4,317 Total revenue $ 60,989 $ 35,633 $ 106,260 $ 62,263 June 30, December 31, Long-lived assets United States $ 13,320 $ 7,195 Other 12,775 12,534 Total long-lived assets $ 26,095 $ 19,729

Net Earnings (Loss) per Commo_2

Net Earnings (Loss) per Common Share (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Reconciliation of Net Income and Common Stock Share Amounts Used in the Computation of Basic and Diluted Earnings Per Share	A reconciliation of net earnings (loss) and common stock share amounts used in the computation of basic and diluted earnings (loss) per common share is presented below. Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Basic and dilutive earnings (loss) per common share: Net income (loss) attributable to Blade Air Mobility, Inc. $ (12,232) $ 8,412 $ (22,424) $ (2,600) Less: Undistributed earnings allocated to nonvested restricted stockholders — (256) — — Basic net earnings (loss) available to common stockholders (12,232) 8,156 (22,424) (2,600) Add: Undistributed earnings allocated to nonvested restricted stockholders — 256 — — Less: Reallocation of undistributed loss to nonvested restricted stockholders — (233) — — Diluted net earnings (loss) available to common stockholders (12,232) $ 8,179 $ (22,424) $ (2,600) Total weighted-average basic common shares outstanding 73,169,003 71,051,523 72,584,138 70,913,597 Effect of dilutive securities: Stock options — 7,445,833 — — Total effect of dilutive securities — 7,445,833 — — Total weighted-average diluted common shares outstanding 73,169,003 78,497,356 72,584,138 70,913,597 Net (loss) earnings per common share: Basic earnings (loss) per common share $ (0.17) $ 0.11 $ (0.31) $ (0.04) Dilutive earnings (loss) per common share $ (0.17) $ 0.10 $ (0.31) $ (0.04)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following table represents common stock equivalents that were excluded from the computation of diluted earnings (loss) per common share for the three and six months ended June 30, 2023 and 2022 because the effect of their inclusion would be anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Warrants to purchase shares of common stock 14,166,644 14,166,644 14,166,644 14,166,644 Options to purchase shares of common stock 7,303,079 — 7,303,079 7,644,533 Restricted shares of common stock 6,780,664 1,051,549 6,780,664 2,354,229 Total potentially dilutive securities 28,250,387 15,218,193 28,250,387 24,165,406

Commitment and Contingencies (T

Commitment and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Unrecorded Unconditional Purchase Obligations Disclosure	These future unfulfilled obligations were as follows: For the Year Ended December 31 Total Unfulfilled Obligation Immediate Termination (1) Termination for Convenience (2) Remainder of 2023 $ 8,892 $ 2,711 $ 2,711 2024 18,876 10,780 3,733 2025 21,119 13,024 2,524 2026 19,784 11,689 1,189 2027 18,595 10,500 — 2028 18,595 10,500 — 2029 - 2032 (each year) 8,095 — — __________ (1) Within total unfulfilled obligation, the following amounts are where Blade has the ability for immediate termination if a government authority enacts travel restrictions. (2) Within total unfulfilled obligation, the following amounts are where Blade could terminate for convenience upon 30 or 60 days’ notice, with a one-year annual minimum guarantee being pro-rated as of the termination date.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2023 and December 31, 2022, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. Level June 30, 2023 December 31, 2022 Warrant liabilities - Public Warrants 1 $ 5,810 $ 4,583 Warrant liabilities - Private Warrants 2 3,169 2,500 Fair value of aggregate warrant liabilities $ 8,979 $ 7,083
Schedule of Change in Fair Value of Warrant Liabilities	The following table presents the changes in fair value of the warrant liabilities: Public Warrants Private Placement Warrants Total Warrant Liability Fair value as of January 1, 2023 $ 4,583 $ 2,500 $ 7,083 Change in fair value of warrant liabilities 1,227 669 1,896 Fair value as of June 30, 2023 $ 5,810 $ 3,169 $ 8,979

Description of Business and S_3

Description of Business and Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Held-to-maturity securities balance	$ 132,342	$ 130,382
Market value of held-to-maturity securities	132,318	130,352
Other short-term investments balance	0	20,358
Other short-term investments	0	20,460
Allowance for credit losses	$ 63	$ 0

Revenue - Narrative (Details)

Revenue - Narrative (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($) Segment mi lineOfBusiness	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Concentration Risk [Line Items]
Deferred revenue | $	$ 10,014		$ 6,709
Customer credit, period	1 year
Revenue recognized | $	$ 3,405	$ 3,603
Number of business lines | lineOfBusiness	3
Number of reportable segments | Segment	2
Minimum
Concentration Risk [Line Items]
Number of miles | mi	10
Maximum
Concentration Risk [Line Items]
Number of miles | mi	100

Revenue - Rollforward of Contra

Revenue - Rollforward of Contract Liability Balance (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Contract With Customer Liability [Roll Forward]
Balance, beginning of period	$ 6,709	$ 5,976
Additions	34,830	36,662
Revenue recognized	(31,525)	(34,138)
Balance, end of period	$ 10,014	$ 8,500

Revenue - Disaggregated Revenue

Revenue - Disaggregated Revenue by Product Line (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disaggregation of Revenue [Line Items]
Revenue	$ 60,989	$ 35,633	$ 106,260	$ 62,263
Passenger
Disaggregation of Revenue [Line Items]
Revenue	26,590	18,384	45,094	32,339
Medical
Disaggregation of Revenue [Line Items]
Revenue	34,399	17,249	61,166	29,924
Short Distance | Passenger
Disaggregation of Revenue [Line Items]
Revenue	19,184	10,963	29,609	15,166
Jet and Other | Passenger
Disaggregation of Revenue [Line Items]
Revenue	7,406	7,421	15,485	17,173
MediMobility Organ Transport | Medical
Disaggregation of Revenue [Line Items]
Revenue	$ 34,399	$ 17,249	$ 61,166	$ 29,924

Right-of-Use Asset and Operat_3

Right-of-Use Asset and Operating Lease Liability - Narrative (Details) $ in Thousands	1 Months Ended	6 Months Ended
	Feb. 28, 2023 aircraft	Jun. 30, 2023 USD ($) aircraft	Dec. 31, 2022 USD ($)
Lessee, Lease, Description [Line Items]
Operating right-of-use asset		$ 23,186	$ 17,692
Operating lease liability, current		4,380	3,362
Operating lease liability, long-term		$ 19,833	14,970
February 2023 Aircraft Lease
Lessee, Lease, Description [Line Items]
Operating lease, term of contract	3 years
Number of aircrafts | aircraft	3
April 2022 Aircraft Lease
Lessee, Lease, Description [Line Items]
Operating lease, term of contract		3 years
Number of aircrafts | aircraft		6
March 2023 Aircraft Lease
Lessee, Lease, Description [Line Items]
Operating lease, term of contract		5 years
Number of aircrafts | aircraft		7
Term of contract, extension		2 years
Aircraft Lease
Lessee, Lease, Description [Line Items]
Agreement termination notice period		60 days
Operating right-of-use asset		$ 20,691	14,916
Operating lease liability, current		2,729	1,748
Operating lease liability, long-term		$ 18,921	$ 13,705

Right-of-Use Asset and Operat_4

Right-of-Use Asset and Operating Lease Liability - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Operating leases:
Operating right-of-use asset	$ 23,186	$ 17,692
Operating lease liability, current	4,380	3,362
Operating lease liability, long-term	$ 19,833	$ 14,970

Right-of-Use Asset and Operat_5

Right-of-Use Asset and Operating Lease Liability - Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Lease cost:
Short-term lease cost	$ 126	$ 59	$ 220	$ 97
Operating lease cost	494	227	961	410
Operating lease cost - Cost of revenue	1,150	250	2,140	250
Total	$ 1,770	$ 536	$ 3,321	$ 757

Right-of-Use Asset and Operat_6

Right-of-Use Asset and Operating Lease Liability - Other Lease Information (Details)	Jun. 30, 2023
Leases [Abstract]
Weighted-average discount rate – operating lease	9.10%
Weighted-average remaining lease term – operating lease (in years)	6 years 8 months 12 days

Right-of-Use Asset and Operat_7

Right-of-Use Asset and Operating Lease Liability - Expected Annual Minimum Lease Payments (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Leases [Abstract]
Remainder of 2023	$ 3,275
2024	6,189
2025	5,030
2026	3,997
2027	3,857
Thereafter	10,597
Total future minimum lease payments, undiscounted	32,945
Less: Imputed interest for leases in excess of one year	(8,732)
Present value of future minimum lease payments	$ 24,213

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activities (Details) - Options - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Options
Outstanding - beginning balance (in shares)	7,603,864
Granted (in shares)	0
Exercised (in shares)	(300,785)
Forfeited (in shares)	0
Outstanding - ending balance (in shares)	7,303,079	7,603,864
Exercisable at period end (in shares)	7,303,079
Weighted Average Exercise Price
Outstanding - beginning balance (in dollars per share)	$ 0.19
Granted (in dollars per share)	0
Exercised (in dollars per share)	0.18
Forfeited (in dollars per share)	0
Outstanding - ending balance (in dollars per share)	0.19	$ 0.19
Exercisable at period end (in dollars per share)	0.19
Weighted Average Grant Date Fair Value
Outstanding - beginning balance (in dollars per share)	0.21
Granted (in dollars per share)	0
Exercised (in dollars per share)	0.24
Forfeited (in dollars per share)	0
Outstanding - ending balance (in dollars per share)	0.21	$ 0.21
Exercisable at period end (in dollars per share)	$ 0.21
Additional Disclosures
Weighted Average Remaining Life (years)	4 years 1 month 6 days	4 years 7 months 6 days
Weighted Average Remaining Life, Exercisable (years)	4 years 1 month 6 days
Intrinsic Value	$ 27,402	$ 25,795
Intrinsic Value, Exercisable	$ 27,402

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 2,797	$ 1,844	$ 5,679	$ 3,942
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	97,846		275,235
Compensation costs to be amortized			$ 29,480
Weighted average amortization period			3 years 1 month 6 days
Restricted Stock And Restricted Stock Units | 2021 Equity Incentive Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Restricted Stock Activity (Details) - Restricted Stock Units (RSUs) - $ / shares	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Restricted Stock Units
Non-vested at beginning of the period (in shares)		7,466,636
Granted (in shares)	97,846	275,235
Vested (in shares)		(834,924)
Forfeited (in shares)		(126,283)
Non-vested at end of the period (in shares)	6,780,664	6,780,664
Weighted Average Grant Date Fair Value
Non-vested at beginning of the period (in dollars per share)		$ 5.52
Granted (in dollars per share)		3.11
Vested (in dollars per share)		6.61
Forfeited (in dollars per share)		5.77
Non-vested at end of the period (in dollars per share)	$ 5.29	$ 5.29

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 2,797	$ 1,844	$ 5,679	$ 3,942
Software development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	293	254	461	529
General and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	2,376	1,495	5,012	3,218
General and administrative | Stock Options And Restricted Stock | Trinity Air Medical, Inc
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense			339
Selling and marketing
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 128	$ 95	$ 206	$ 195

Segment and Geographic Inform_3

Segment and Geographic Information - Narrative (Details)	6 Months Ended
	Jun. 30, 2023 Segment
Segment Reporting [Abstract]
Number of reportable segments	2

Segment and Geographic Inform_4

Segment and Geographic Information - Schedule of Financial Data by Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	$ 60,989	$ 35,633	$ 106,260	$ 62,263
Gross Profit	10,369	5,111	17,533	8,034
All other operating costs	(22,578)	(14,844)	(42,569)	(31,457)
Segment net loss	(12,209)	(9,733)	(25,036)	(23,423)
Unallocated corporate costs & software development	(7,875)	(8,101)	(17,221)	(16,797)
Other non-operating income	(399)	18,145	2,040	20,823
(Loss) income before income taxes	$ (12,608)	$ 8,412	$ (22,996)	$ (2,600)
Gross Profit, Margin	17%	14.30%	16.50%	12.90%
Goodwill	$ 39,797		$ 39,797		$ 39,445
Operating Segments
Segment Reporting, Revenue Reconciling Item [Line Items]
Segment net loss	(4,334)	$ (1,632)	(7,815)	$ (6,626)
Passenger
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	26,590	18,384	45,094	32,339
Gross Profit	$ 4,642	$ 2,478	$ 7,454	$ 3,167
Gross Profit, Margin	17.50%	13.50%	16.50%	9.80%
Goodwill	$ 26,469		$ 26,469		26,117
Passenger | Operating Segments
Segment Reporting, Revenue Reconciling Item [Line Items]
Segment net loss	(3,837)	$ (2,326)	(8,955)	$ (7,842)
Medical
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	34,399	17,249	61,166	29,924
Gross Profit	$ 5,727	$ 2,633	$ 10,079	$ 4,867
Gross Profit, Margin	16.60%	15.30%	16.50%	16.30%
Goodwill	$ 13,328		$ 13,328		$ 13,328
Medical | Operating Segments
Segment Reporting, Revenue Reconciling Item [Line Items]
Segment net loss	$ (497)	$ 694	$ 1,140	$ 1,216

Segment and Geographic Inform_5

Segment and Geographic Information - Schedule of Revenues and Long-Lived Assets by Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 60,989	$ 35,633	$ 106,260	$ 62,263
Long-lived assets	26,095	19,729	26,095	19,729
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	51,991	33,103	89,990	57,946
Long-lived assets	13,320	7,195	13,320	7,195
Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	8,998	2,530	16,270	4,317
Long-lived assets	$ 12,775	$ 12,534	$ 12,775	$ 12,534

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income tax benefit	$ (376)	$ 0	$ (572)	$ 0

Net Earnings (Loss) per Commo_3

Net Earnings (Loss) per Common Share - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Basic and dilutive earnings (loss) per common share:
Net income (loss) attributable to Blade Air Mobility, Inc.	$ (12,232)	$ 8,412	$ (22,424)	$ (2,600)
Less: Undistributed earnings allocated to nonvested restricted stockholders	0	(256)	0	0
Basic net earnings (loss) available to common stockholders	(12,232)	8,156	(22,424)	(2,600)
Add: Undistributed earnings allocated to nonvested restricted stockholders	0	256	0	0
Less: Reallocation of undistributed loss to nonvested restricted stockholders	0	(233)	0	0
Diluted net earnings (loss) available to common stockholders	$ (12,232)	$ 8,179	$ (22,424)	$ (2,600)
Total weighted-average basic common shares outstanding (in shares)	73,169,003	71,051,523	72,584,138	70,913,597
Effect of dilutive securities:
Stock options (in shares)	0	7,445,833	0	0
Total effect of dilutive securities (in shares)	0	7,445,833	0	0
Diluted (in shares)	73,169,003	78,497,356	72,584,138	70,913,597
Net (loss) earnings per common share:
Basic (loss) earnings per common share (in dollars per share)	$ (0.17)	$ 0.11	$ (0.31)	$ (0.04)
Diluted (loss) earnings per common share (in dollars per share)	$ (0.17)	$ 0.10	$ (0.31)	$ (0.04)

Net Earnings (Loss) per Commo_4

Net Earnings (Loss) per Common Share - Anti-dilutive Securities (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Effect of dilutive securities:
Potentially dilutive securities (in shares)	28,250,387	15,218,193	28,250,387	24,165,406
Warrants to purchase shares of common stock
Effect of dilutive securities:
Potentially dilutive securities (in shares)	14,166,644	14,166,644	14,166,644	14,166,644
Options to purchase shares of common stock
Effect of dilutive securities:
Potentially dilutive securities (in shares)	7,303,079	0	7,303,079	7,644,533
Restricted shares of common stock
Effect of dilutive securities:
Potentially dilutive securities (in shares)	6,780,664	1,051,549	6,780,664	2,354,229

Commitment and Contingencies -

Commitment and Contingencies - Schedule of Future Unfulfilled Obligations (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Loss Contingencies [Line Items]
Unfulfilled purchase obligation, minimum period guaranteed as of termination date	1 year
Termination Upon Notice
Loss Contingencies [Line Items]
Remainder of 2023	$ 2,711
2024	3,733
2025	2,524
2026	1,189
2027	0
2028	0
2029 - 2032 (each year)	$ 0
Termination Upon Notice | Minimum
Loss Contingencies [Line Items]
Unfulfilled purchase obligation, termination notice period	30 days
Termination Upon Notice | Maximum
Loss Contingencies [Line Items]
Unfulfilled purchase obligation, termination notice period	60 days
Airline Capacity Purchase Arrangements
Loss Contingencies [Line Items]
Remainder of 2023	$ 8,892
2024	18,876
2025	21,119
2026	19,784
2027	18,595
2028	18,595
2029 - 2032 (each year)	8,095
Airline Capacity Purchase Arrangements | Immediate Termination Option
Loss Contingencies [Line Items]
Remainder of 2023	2,711
2024	10,780
2025	13,024
2026	11,689
2027	10,500
2028	10,500
2029 - 2032 (each year)	$ 0

Commitment and Contingencies _2

Commitment and Contingencies - Narrative (Details) - Trinity Air Medical, Inc - USD ($) $ in Millions	Jun. 30, 2023	Sep. 15, 2021
Loss Contingencies [Line Items]
Percentage of equity interest acquired		100%
Earnout to be paid in cash, percent		70%
Business Combination, Earnout To Be Paid In Cash	$ 3

Warrant Liabilities (Details)

Warrant Liabilities (Details)	6 Months Ended
	Jun. 30, 2023 $ / shares
Class of Warrant or Right [Line Items]
Notice of redemption	30 days
Redemption commencement period	90 days
Minimum
Class of Warrant or Right [Line Items]
Share price (in dollars per share)	$ 10
Public Warrants
Class of Warrant or Right [Line Items]
Redemption price of warrants (in dollars per share)	$ 0.01
Notice of redemption	30 days
Redemption, threshold trading days	20 days
Redemption, consecutive trading days	30 days
Redemption, period prior to notice of redemption	3 days
Public Warrants | Minimum
Class of Warrant or Right [Line Items]
Share price (in dollars per share)	$ 18

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of aggregate warrant liabilities	$ 8,979	$ 7,083
Public Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of aggregate warrant liabilities	5,810	4,583
Private Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of aggregate warrant liabilities	3,169	2,500
Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of aggregate warrant liabilities	8,979	7,083
Fair Value, Recurring | Level 1 | Public Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of aggregate warrant liabilities	5,810	4,583
Fair Value, Recurring | Level 2 | Private Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of aggregate warrant liabilities	$ 3,169	$ 2,500

Fair Value Measurements - Chang

Fair Value Measurements - Change in Fair Value of Warrant Liabilities (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Fair value as of January 1, 2023	$ 7,083
Change in fair value of warrant liabilities	1,896
Fair value as of June 30, 2023	$ 8,979
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Warrant liability
Public Warrants
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Fair value as of January 1, 2023	$ 4,583
Change in fair value of warrant liabilities	1,227
Fair value as of June 30, 2023	5,810
Private Placement Warrants
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Fair value as of January 1, 2023	2,500
Change in fair value of warrant liabilities	669
Fair value as of June 30, 2023	$ 3,169